8-K current report · filed Oct 29, 2026

BridgeBio Pharma, Inc. (BBIO) 8-K Current Report: October 29, 2026

Item EX-99.1Item 2.02BBIO overview

Short answer

BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for period ended September 30, 2026, covering financial performance and recent business updates.

BridgeBio Pharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026, covering financial performance and recent business updates
  • Exhibit 99.1 contains the full earnings release, the primary source for detailed results and guidance
  • Market focus: BridgeBio’s pipeline progress and cash position alongside quarterly operating performance

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $353.2M, including Attruby product revenue $253.2M, up $145.2M year over year
  • Attruby adoption accelerating in treatment-naïve patients, strengthening commercial momentum in ATTR-CM
  • Cash, equivalents and marketable securities $1.5B, supporting three imminent launches and indication expansion
  • Three Priority Review FDA decisions: BBP-418 November 27, 2026, infigratinib February 4, 2027, encaleret May 8, 2027
  • Q3 net loss attributable to common stockholders $83.0M, while operating loss narrowed to $11.6M despite launch investments

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BridgeBio Pharma, Inc. 8-K filings

Get the next BBIO 8-K as it lands

Follow BBIO for push alerts, or ask the research agent what this filing means.